US FDA approves Jazz Pharma's drug for rare brain tumor
(Reuters) -The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older.
The approval expands Jazz's cancer drug portfolio beyond its existing treatments for certain blood and lung cancers.
This is the first FDA-approved systemic therapy for diffuse midline glioma with a specific mutation that has progressed despite prior treatments, the agency said.
The drug, Modeyso, is expected to become available in the U.S. in the coming weeks and is administered as a once-weekly oral capsule.
Diffuse midline glioma (DMG) is a rare and aggressive brain tumor that primarily affects children and young adults. It develops in the brain's and spinal cord's midline structures, such as the brainstem, thalamus, and spinal cord.
An estimated 3,940 people are living with this tumor in the United States, according to NIH data.
The FDA decision was based on data from 50 patients in five clinical studies, showing that the drug helped shrink tumors in about 22% of cases. Among those who responded, the benefit lasted a median of just over 10 months.
"We think it fits very well in terms of addressing a very high unmet need," said Rob Iannone, Chief Medical Officer at Jazz Pharmaceuticals, ahead of the decision.
Jazz Pharmaceuticals acquired the drug in March through its $935 million purchase of Chimerix.
The company says it plans to work with doctors and advocates to make the treatment available as quickly as possible.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
22 minutes ago
- CNN
FDA official returns to agency after Loomer-led ouster
Federal agencies ActivismFacebookTweetLink Follow Dr. Vinay Prasad, a controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has returned to his job weeks after resigning amid pressure from the White House and right-wing activist Laura Loomer. 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' said Health and Human Services spokesperson Andrew Nixon in a statement to CNN on Saturday. Nixon did not respond to CNN's inquiry about whether Prasad will also return to his role as FDA chief medical and scientific officer. In late July, Prasad, a hematologist oncologist, said he was resigning because he 'did not want to be a distraction to the great work of the FDA' and had 'decided to return to California and spend more time with his family.' Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Loomer, who has extraordinary access to President Donald Trump. Loomer had taken shots at Prasad on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad had been a vocal critic of some of the agency's drug approvals, as well as the government's response and vaccine policies during the Covid-19 pandemic. Loomer, reacting to the news of Prasad's return in a Saturday post on X, called it an 'egregious personnel decision' and said she planned to '(ramp) up my exposes of officials within HHS and FDA' in the coming weeks. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CBER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions. CNN's Meg Tirrell, Sarah Owermohle, and Adam Cancryn contributed to this report.
The Hill
23 minutes ago
- The Hill
FDA reinstates ousted top vaccine regulator Vinay Prasad
Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services (HHS). 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' an HHS spokesperson told The Hill in a statement. 'Neither the White House nor HHS will allow the fake news media to distract from the critical work the FDA is carrying out under the Trump administration.' Prasad's July 30 resignation as the FDA's chief science officer followed criticism from right-wing figures — including activist Laura Loomer and former Sen. Rick Santorum (R-Pa.) — that ran parallel to a regulatory showdown with drug manufacturers over a gene therapy treatment for boys with Duchenne muscular dystrophy. Loomer, a key ally of President Trump with noticeable influence, lavished attacks on the FDA official in recent weeks — calling him a 'saboteur' and 'trojan horse' for HHS's 'Make America Healthy Again' initiative. Prasad was named head of the FDA's Center for Biologics Evaluation and Research in early May as a replacement for Peter Marks, who resigned from the position in March after clashing with HHS Secretary Robert F. Kennedy Jr. The doctor, just one of several health officials tapped by Trump who criticized COVID-19 vaccines, had been in the role for less than three months when the FDA announced he would step down. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' an HHS spokesperson said at the time. 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA.' The division at the time was also involved in a dispute between the administration and Sarepta Therapeutics. The FDA had paused shipments and clinical trials of its Elevidys treatment for those with Duchenne muscular dystrophy following reports of two patients that died after receiving the drug. Prior to his role in the administration, Prasad had argued against the treatment's approval after Marks overrode multiply agency reviews. He also recently made headlines for restricting the approval of two COVID-19 vaccines while disregarding recommendations from government scientists. Two memos issued last month by the FDA showed how the doctor personally intervened to place limitations on drugmakers Novavax and Moderna after their coronavirus shots were approved for anyone 12 years or older.
CNN
24 minutes ago
- CNN
FDA official returns to agency after Loomer-led ouster
Dr. Vinay Prasad, a controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has returned to his job weeks after resigning amid pressure from the White House and right-wing activist Laura Loomer. 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' said Health and Human Services spokesperson Andrew Nixon in a statement to CNN on Saturday. Nixon did not respond to CNN's inquiry about whether Prasad will also return to his role as FDA chief medical and scientific officer. In late July, Prasad, a hematologist oncologist, said he was resigning because he 'did not want to be a distraction to the great work of the FDA' and had 'decided to return to California and spend more time with his family.' Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Loomer, who has extraordinary access to President Donald Trump. Loomer had taken shots at Prasad on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad had been a vocal critic of some of the agency's drug approvals, as well as the government's response and vaccine policies during the Covid-19 pandemic. Loomer, reacting to the news of Prasad's return in a Saturday post on X, called it an 'egregious personnel decision' and said she planned to '(ramp) up my exposes of officials within HHS and FDA' in the coming weeks. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CBER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions. CNN's Meg Tirrell, Sarah Owermohle, and Adam Cancryn contributed to this report.
